Collaborative Interactions

Within DF/HCC, the Gastrointestinal Malignancies Program has engaged in a wide range of collaborations across disciplines and institutions. Collaborative interactions within this Program include:

• Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) project
• Improving Cancer Care in Massachusetts (CAMA)

• Development of a mouse model for pancreatic cancer
• Hedgehog in pancreatic cancer tumorigenesis
• Development/Cancer- Ramesh Shivdasani

• Phase II study of bevacizumab with gemcitabine and oxaliplatin in HCC (Andrew Zhu, Keith Sutart, and Charles Fuchs, Principal Investigators; DF/HCC protocol number 03-390).
• Phase I Bevacizumab with 5-FU and radiation therapy in Rectal Cancer (Jeffrey Clark and Charles Fuchs, Principal Investigators; DF/HCC 02-025).
• Oral SU011 in patients with metastatic carcinoid or pancreatic neuroendocrine tumors (Matthew Kulke, Keith Stuart, and David Ryan, Principal Investigators; DF/HCC 02-317)
• Understanding racial disparities in colon cancer outcomes.  John Ayanian (J. Clin Oncol 2003)

• 
  • Disease-based Programs
    • Breast Cancer
    • Cutaneous Oncology and Melanoma
    • Gastrointestinal Malignancies
      • -
        Specific Aims
      • -
        Funding Opportunities
      • -
        Members
      • +
        Collaborative Interactions
      • -
        Clinical Trials
      • -
        Resources
      • -
        Contact
    • Gynecologic Cancer
    • Head and Neck Cancer
    • Kidney Cancer
    • Leukemia
    • Lung Cancer
    • Lymphoma and Myeloma
    • Neuro-Oncology
    • Prostate Cancer
    • Sarcoma
  • Discipline-based Programs
  • Joining a Program
• 
• 
• 
• 
• 
•